A Phase 1 Study of Prasugrel in Subjects with Sickle Cell Disease: Impact on Ex Vivo Platelet Reactivity
Joseph A. Jakubowski(Indiana Biosciences Research Institute), Christopher D. Payne(Eli Lilly (United States)), Andrew L. Frelinger(University of Nottingham), D. Richard Lachno(Alzheimer's Association), Chunmei Zhou(Eli Lilly (United States)), Kenneth J. Winters(Eli Lilly (United States)), Jo Howard(National Health Service), David S. Small(Eli Lilly (United States)), Stipo Jurčević(King's College London)
Cited by 0
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617